Neopharma

Neopharma

Neopharma

Neopharma commenced operations in 2003 and the first set of manufacturing facilities were planned on an investment outlay of USD25 million. The organization’s inspiration stems from the vision to locally manufacture world class pharmaceuticals at affordable prices. Neopharmas global presence is supported by 5 manufacturing facilities spread across 3 continents delivering branded and generic formulations, and active pharmaceutical ingredients (APIs). The therapeutic segments covered by our portfolio of over 100 high-quality molecules include anti-infectives, neurology, cardiology, orthopedics, diabetology, gastroenterology, urology, dermatology, gynecology, respiratory, dental and nutritionals. Driven by innovation, Neopharma lays strong emphasis on research, especially towards development of processes and products that are patent non-infringing. Neopharma currently caters to over 50 international markets including Middle East, Africa, CIS, Far East and South East Asia. 

 

Contact Information

Neopharma
Plot A-1 89-95,
Industrial City of Abu Dhabi (ICAD),
Mussafah,
P.O. Box 72900,
Abu Dhabi,
United Arab Emirates.